View More Recent Stories

Mar 3, 2025 11:48AM Ocular Therapeutix (OCUL) PT Lowered to $17 at BofA Securities, PT $17
Mar 3, 2025 11:47AM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19
Mar 3, 2025 07:10AM Ocular Therapeutix (OCUL) Misses Q4 EPS by 4c
Feb 5, 2025 01:16PM Raymond James Reiterates Strong Buy Rating on Ocular Therapeutix (OCUL), PT $19
Jan 14, 2025 07:03AM Ocular Therapeutix (OCUL) Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI in NPDR
Jan 2, 2025 12:51PM Biopharma 2025 Preview: 'Piper Sandler Sees Lots of Upside Opportunity'
Dec 18, 2024 05:10PM Clear Street Starts Ocular Therapeutix (OCUL) at Buy
Dec 3, 2024 06:59AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
Dec 3, 2024 06:32AM Baird Reiterates Outperform Rating on Ocular Therapeutix (OCUL)
Nov 15, 2024 06:51AM Ocular Therapeutix (OCUL) PT Raised to $15 at H.C. Wainwright
Nov 14, 2024 07:04AM Ocular Therapeutix (OCUL) Tops Q3 EPS by 2c
Nov 12, 2024 07:31AM Ocular Therapeutix (OCUL) Appoints Namrata Saroj, OD, as Chief Business Officer
Oct 16, 2024 06:54AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
Oct 15, 2024 07:31AM Ocular Therapeutix (OCUL) Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI in Wet AMD
Sep 19, 2024 07:40AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
Sep 3, 2024 08:06AM Ocular Therapeutix (OCUL) Appoints Donald Notman as COO
Aug 7, 2024 07:14AM Ocular Therapeutix (OCUL) Misses Q2 EPS by 4c
Aug 7, 2024 07:02AM Ocular Therapeutix (OCUL) Announces FDA Feedback That SOL-R Trial is Appropriate as a Registrational Study in Wet AMD
Jul 17, 2024 07:56AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
Jul 12, 2024 08:18AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
Jun 27, 2024 09:31AM Piper Sandler Reiterates Overweight Rating on Ocular Therapeutix (OCUL)
Jun 20, 2024 06:48AM TD Cowen Upgrades Ocular Therapeutix (OCUL) to Buy
Jun 14, 2024 03:13PM JMP Securities Reiterates Market Outperform Rating on Ocular Therapeutix (OCUL)
Jun 14, 2024 07:57AM H.C. Wainwright Reiterates Buy Rating on Ocular Therapeutix (OCUL)
Jun 14, 2024 07:47AM TD Cowen Reiterates Hold Rating on Ocular Therapeutix (OCUL)
View More Recent Stories